贝伐珠单抗联合埃克替尼克服一例非小细胞肺癌患者奥希替尼耐药
张玲， 孙雷， 穆晓燕， 季有信 - Chinese Medical Sciences Journal, 2019 - cmsj.cams.cn
… therapy, partial response was achieved. Patients of non-small-cell lung cancer maintain …
T790M mutation is a genetic change after Osimertinib treatment. This case suggests the re-…
T790M mutation is a genetic change after Osimertinib treatment. This case suggests the re-…
[HTML][HTML] 厄洛替尼致间质性肺病4 例并文献复习
吴小玲， 高广辉， 任胜祥， 周彩存 - Chinese Journal of Lung …, 2012 - ncbi.nlm.nih.gov
… Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
which are used for non-small cell lung … ILD induced by gefitinib been often described, but …
which are used for non-small cell lung … ILD induced by gefitinib been often described, but …
[HTML][HTML] 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
黄珺霞， 王红 - Chinese Journal of Lung Cancer, 2022 - ncbi.nlm.nih.gov
… 肺癌（non-small cell lung … advanced NSCLC patients with EGFR mutations, EGFR-tyrosine
kinase inhibitors (EGFR-TKIs), such as Gefitinib, Afatinib, Oxitinib and other targeted therapies …
kinase inhibitors (EGFR-TKIs), such as Gefitinib, Afatinib, Oxitinib and other targeted therapies …
[HTML][HTML] 晚期非小细胞肺癌探索性四线及以上治疗的回顾性分析
王仙凤， 黄媚娟， 任莉， 徐泳， 李潞， 侯梅… - … Journal of Lung …, 2014 - ncbi.nlm.nih.gov
… A common consensus has been reached regarding first- and second-line therapies for
advanced non-small cell lung cancer (NSCLC). The newest guideline from National …
advanced non-small cell lung cancer (NSCLC). The newest guideline from National …
非小细胞肺癌术后表皮生长因子受体-酪氨酸激酶抑制剂辅助治疗研究进展
刘哲峰， 焦顺昌 - 解放军医学院学报, 2015 - xuebao.301hospital.com.cn
… free survival of adjuvant erlotinib or gefitinib in patients with resected lung … gefitinib in resected
stage IIIA-N2 nonsmall cell lung cancer harbouring EGFR mutations :a randomized, phase …
stage IIIA-N2 nonsmall cell lung cancer harbouring EGFR mutations :a randomized, phase …
[PDF][PDF] 晚期非小细胞肺癌一线化疗疗效与生存关系的分析
林立平， 向晓娟， 黄河， 赵洪云， 张阳， 吴敬勋， 赵媛媛… - 2008 - researchgate.net
… Corresponding author: ZHANG Li , E-mail: zhangli6@mail.sysu.edu.cn [Abstract] Background
and objective Most patients with advanced non-small cell lung cancer (NSCLC) treated …
and objective Most patients with advanced non-small cell lung cancer (NSCLC) treated …
[HTML][HTML] EGFR-TKI 联合放疗治疗晚期非小细胞肺癌的研究进展
李夏南， 朱广迎 - Chinese Journal of Lung Cancer, 2014 - ncbi.nlm.nih.gov
… ) made huge progress in treatment of lung cancer. EGFR-… EGFR-mutated patients in stage
Ⅳ non-small cell lung cancer (… CRT) and gefitinib (G) in stage Ⅲ non-small cell lung cancer (…
Ⅳ non-small cell lung cancer (… CRT) and gefitinib (G) in stage Ⅲ non-small cell lung cancer (…
[HTML][HTML] 存在驱动基因突变肺鳞癌患者的临床病理特征及预后分析
张童童， 李峻岭 - Chinese Journal of Lung Cancer, 2016 - ncbi.nlm.nih.gov
… ), and KRAS are common driver genes in non-small cell lung cancer (NSCLC). Molecular
targeted therapy increases the overall response rate and progression-free survival (PFS) of …
targeted therapy increases the overall response rate and progression-free survival (PFS) of …
[HTML][HTML] 培美曲塞/顺铂二线治疗晚期非小细胞肺癌： 一例报告及文献复习
赵长林， 孙红芹， 杨扬， 代晓楠 - Chinese Journal of Lung Cancer, 2010 - ncbi.nlm.nih.gov
… value of treatment of advanced non-small cell lung cancer … GC, the sequential treatment
with gefitinib, used pemetrexed … , after the treatment of first line and maintenance therapy, …
with gefitinib, used pemetrexed … , after the treatment of first line and maintenance therapy, …
[PDF][PDF] 鸦胆子油乳联合NP 方案治疗晚期非小细胞肺癌的临床疗效观察
任英红， 刘海洋， 全卫涛 - 2012 - biomed.cnjournals.com
… with advanced non-small cell lung cancer (NSCLC) patients. … of advanced non-small cell
lung cancer: maintenance therapy [J]. … Erlotinib or gefitinib for the treatment of relapsed platinum …
lung cancer: maintenance therapy [J]. … Erlotinib or gefitinib for the treatment of relapsed platinum …